Zelira Therapeutics (ASX:ZLD) has announced a successful direct capital raise of A$1.77M from US-based investors to provide additional working capital for further progressing its strategies and FDA clinical trials.
Zelira Therapeutics is a global biopharmaceutical company that researches, develops and commercialises clinically validated cannabinoid-based medicines.
The company says it owns a portfolio of proprietary revenue-generating products, as well as a pipeline of candidates undergoing clinical development.
Zelira Therapeutics also says it generates revenue from two proprietary medications, HOPEĀ® and ZENIVOLĀ®.